PAP
BCRX icon

Persistent Asset Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Persistent Asset Partners’s Portfolio BCRX Stock Details BCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-51,701
Closed -$403K – 348
2025
Q4 		$403K Buy
+51,701
New +$374K 0.18% 149

Other funds holding BCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Persistent Asset Partners's BCRX Position: Q1 2026 in Review

Persistent Asset Partners sold out of BioCryst Pharmaceuticals (BCRX) in Q1 2026, closing a stake of 51,701 shares — an estimated $403K sold.

Persistent Asset Partners first reported a position in BCRX in Q4 2025 and held it in 1 quarter. The position peaked at $403K in Q4 2025. 302 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

  • Persistent Asset Partners reported no remaining BioCryst Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 51,701 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $403K.
  • Persistent Asset Partners first reported a position in BioCryst Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • Persistent Asset Partners's BioCryst Pharmaceuticals position peaked at $403K in Q4 2025.
  • 302 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Persistent Asset Partners's 13F filing for Q1 2026, filed 12 May 2026.